查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2112600

基於雲端的藥物發現平台市場：按雲端服務類型、雲端類型、最終用戶和地區分類－趨勢及至2035年的預測

Cloud Based Drug Discovery Platforms Market by Type of Cloud Service, Type of Cloud, End User, and Geographical Regions - Trends and Forecast Till 2035
出版日期: | 出版商: Roots Analysis | 英文 257 Pages | 商品交期: 7-10個工作天內

價格
簡介目錄

基於雲端的藥物發現平台市場概述

全球基於雲端的藥物發現平台市場規模預計將從今年的 42 億美元成長到 2035 年的 114 億美元，預測期內的複合年成長率預計約為 11.7%。

基於雲端的藥物發現平台市場-IMG1

基於雲端的藥物發現平台市場—成長與趨勢

基於雲端的藥物發現平台是託管在網際網路上的軟體生態系統，它透過提供可擴展的運算能力、集中式資料儲存和先進的分析功能，加速新型治療化合物的識別和最佳化。這些平台支援關鍵的藥物發現工作流程，例如標靶識別、分子建模、虛擬篩檢、先導先導化合物最佳化、多組體學數據管理以及地理位置分散的團隊之間的協作研究。

隨著對大量資料（包括生物學、化學、基因組學、轉錄組學和臨床數據）的依賴日益加深，現代藥物研發計畫變得愈發複雜，對能夠大規模處理和解讀這些資料集的平台的需求也日益成長。傳統的本地部署基礎設施往往限制了可擴展性、運算柔軟性和跨職能協作，但雲端平台憑藉集中式資料存取、強大的高效能運算能力以及與人工智慧和機器學習工具的原生整合，能夠很好地克服這些限制。

此外，整個產業轉向數據驅動和人工智慧驅動的藥物發現模式的轉變也推動了雲端技術的應用。製藥和生物技術公司擴大採用雲端基礎設施來識別先導化合物、預測候選化合物的性質、減輕實驗負擔並加速早期決策。隨著合約研究組織 (CRO) 和技術提供者更參與藥物發現計畫中，涵蓋藥物發現、資訊學、生產製造和外部合作夥伴的分散式研究團隊越來越依賴雲端環境來改善協作。

特別是，人工智慧驅動的藥物發現工具的持續進步、雲端運算基礎設施的擴展以及製藥公司與雲端服務提供商之間大規模技術合作的成長，預計將維持市場的長期成長。

成長要素：支持市場擴張的因素

雲端藥物發現平台市場的成長主要得益於人工智慧驅動的藥物發現工作流程的日益普及。製藥和生物技術公司正擴大利用雲端平台中的人工智慧來加速目標識別、分子生成、虛擬篩檢、先導藥物最適化和候選化合物優先排序。雲端基礎設施透過提供可擴展的運算能力、集中式資料存取以及並行運行多個預測模型的能力，為這些工作流程提供了支持，從而避免了建構複雜內部運算基礎設施的巨額資本負擔。這一趨勢也體現在近期推出的平台中。亞馬遜網路服務（AWS）推出了「Amazon Bio Discovery」，該平台提供超過40種人工智慧生物模型，以及人工智慧驅動的模型選擇、計算工作流程設計和濕實驗室檢驗支援。

此外，對可擴展的數據整合和協作研究的需求日益成長。現代藥物研發依賴大規模生物學、化學、基因組學、轉錄組學和真實世界資料集的整合。雲端平台使研究團隊能夠在分散式藥物研發網路中儲存、分析和共用這些資料集，從而加強製藥公司、技術供應商、學術機構和受託研究機構(CRO) 之間的合作。大規模雲端解決方案供應商正在利用夥伴關係來擴展其全球企業發展。默克和Google雲端宣布了一項價值高達 10 億美元的多年合作計劃，整體研發、生產、商業和企業職能部門部署人工智慧和雲端基礎設施。

市場挑戰－阻礙進展的主要障礙

儘管雲端藥物發現平台市場發展勢頭強勁，但仍面臨諸多限制因素。其中最重要的是資料安全、智慧財產權保護和合規性問題。由於這些平台處理高度敏感的數據，包括獨特的分子結構、靶點生物學特性、篩檢結果、患者相關資料集以及競爭對手的研發管線信息，因此數據安全、訪問控制、可審計性和供應商管治在實施過程中至關重要。此外，製藥公司必須確保雲端系統符合監管和資料保護要求，尤其是在平台支援受監管的研究工作流程或產生用於研發決策的證據時。

此外，基於雲端的藥物發現平台的有效性很大程度上取決於輸入資料集的品質和相容性，然而許多機構仍然管理著分散在舊有系統、內部資料庫、實驗室平台和外部來源的研究數據，這使得整合變得複雜。另外，這些平台中使用的AI模型需要經過嚴格的檢驗、可解釋性和情境表現評估，相關人員才能信任其輸出結果，並將其用於藥物發現和開發決策。對於考慮實施此類平台的機構而言，系統互通性和與現有研究基礎設施的整合仍然是關鍵的考慮因素。

基於雲端的藥物發現平台市場—關鍵洞察

本報告詳細分析了目前基於雲端的藥物發現平台市場現狀，並指出了該行業的潛在成長機遇，尤其從分銷商和通路合作夥伴的角度出發。主要發現包括：

  • 資本投入增加－近年來，透過創業投資、私募股權和策略資金籌措，超過40億美元的資金已投入到雲端原生藥物發現技術提供者、人工智慧驅動的研究平台和計算生物學公司。英國生技公司Relation Therapeutics已與葛蘭素史克(GSK)達成一項價值高達1.1億美元的合作協議，共同開發人工智慧驅動的藥物發現模型和人類細胞資料集。
  • 策略聯盟加速發展—市場正見證著雲端服務供應商、製藥公司、生技公司和人工智慧平台開發商之間策略聯盟的日益增加。這些聯盟專注於整合高效能運算、機器學習和多組體學資料管理，旨在加速藥物研發流程、緩解運算瓶頸並支援分散的全球研究團隊。百時美施貴寶宣布採用輝達的下一代人工智慧基礎設施DGX SuperPOD來加速藥物研發，並表示人工智慧相關的開發週期已縮短了20-30%。
  • 監管與數位基礎設施發展－監管機構日益重視人工智慧、雲端運算和數位技術在藥物研發中的作用，並發布了關於電子記錄、人工智慧模型驗證、資料完整性和良好機器學習實踐（GMLP）的最新指南。同時，網路安全標準和雲端合規框架的進步也增強了業界對採用雲端藥物發現平台的信心。
  • 未來重點領域—未來市場成長將取決於實驗室資訊管理系統 (LIMS)、電子實驗記錄本 (ELN)、基因組資料庫和人工智慧藥物發現平台之間互通性的提升。聯邦學習、安全的多方資料共用、可解釋人工智慧和標準化雲端資料架構的普及有望加強組織間的合作，同時應對資料隱私、法規遵循和知識產權保護等挑戰。這些趨勢可能會影響平台的長期應用，並將繼續成為技術提供者和投資者關注的重要指標。

基於雲端的藥物發現平台的市場區隔

Roots Analysis 根據以下參數對全球雲端藥物發現平台市場進行分類：

按雲端服務類型

  • 軟體即服務 (SaaS)
  • 基礎設施即服務 (IaaS)
  • 平台即服務 (PaaS)
  • 其他

按雲類型

  • 混合雲端
  • 公共雲端
  • 私有雲端

最終用戶

  • 製藥和生命科學公司
  • CRO
  • 其他

按地區

  • 北美洲
  • 歐洲
  • 亞太地區
  • 中東和北非
  • 拉丁美洲

基於雲端的藥物發現平台市場－關鍵細分市場分析

SaaS正在推動基於雲端的藥物發現平台市場的發展。

根據我們的市場評估，軟體即服務 (SaaS) 目前在雲端藥物研發平台市場佔最大佔有率。其主導地位源於 SaaS 較低的初始基礎設施要求、較短的部署週期以及基於訂閱的先進藥物研發工具存取權。這些因素使得 SaaS 成為各種規模和計算資源成熟度的組織機構的理想選擇。

在預測期內，平台即服務 (PaaS) 領域預計將實現最高的複合年成長率。這一成長歸功於 PaaS 使製藥和生物技術公司能夠建構、整合和擴展跨人工智慧建模、分子模擬、數據分析和協作研究環境的客製化藥物發現工作流程。

按雲端類型分類，混合雲端佔最大的市場佔有率。

我們的分析表明，混合雲端在基於雲端的藥物研發市場中佔最大佔有率。這是因為混合雲端使製藥和生物技術公司能夠在運算可擴展性與嚴格的安全性和監管要求之間取得平衡。藥物研發工作流程會產生大量敏感數據，包括基因組資料集、分子結構、臨床證據和專有人工智慧模型，這使得許多組織難以完全遷移到公共雲端環境。混合雲端架構允許公司在其私有基礎設施中保留高度敏感的知識產權和受監管數據，同時利用公共雲端執行運算密集任務，例如人工智慧模型訓練、虛擬篩檢和大規模體學分析。

此外，採用混合雲端能夠實現地理位置分散的研究團隊、合約研究組織 (CRO)、學術機構和技術合作夥伴之間的無縫協作，同時又不影響關鍵資料資產的管治。隨著製藥公司不斷採用人工智慧驅動的藥物發現和多方合作研發模式，並同時遵守不斷發展的資料隱私和監管標準，混合雲端環境預計將繼續保持其首選部署模式，從而進一步鞏固主導地位。

北美保持市場領先地位

預計北美將保持其作為全球最大的雲端藥物發現平台區域市場的地位直至 2035 年。這一區域領先地位得益於強大的製藥和生物技術公司網路、先進的雲端基礎設施、人工智慧驅動的藥物發現平台的廣泛應用以及對研發的高額投入。

亞太地區正在崛起成為成長最快的區域市場。

預計亞太地區雲端藥物發現平台市場在預測期內將達到最高的複合年成長率。該地區的成長主要得益於不斷擴大的藥物研發活動、生物技術領域投資的增加以及對具成本效益藥物發現解決方案日益成長的需求。中國、印度、日本和韓國等國家正在加強其數位醫療和生命科學生態系統建設，加速採用雲端平台進行協作式藥物發現、資料管理和運算科學研究。

製藥和生命科學公司佔了終端用戶市場最大的佔有率。

我們的分析表明，製藥和生命科學公司在基於雲端的藥物發現市場中佔最大佔有率。這種主導地位源自於它們廣泛參與整個藥物發現價值鏈，以及對數位化研究能力的持續投入。這些機構產生並管理著大量的生物學、化學、基因組學和臨床數據，這些數據需要可擴展的計算基礎設施來進行儲存、整合和分析。透過利用雲端平台，這些公司可以加速標靶識別、虛擬篩檢、分子建模、人工智慧驅動的預測分析以及先導化合物最佳化，同時減少對高成本的本地基礎設施的依賴。

此外，製藥和生命科學公司越來越依賴雲端環境來支援地理位置分散的研究團隊、合約研究組織 (CRO)、學術機構和技術合作夥伴之間的協作。隨著藥物研發專案日益數據密集化和人工智慧主導，安全共用數據、整合實驗室和計算工作流程以及快速擴展計算資源的能力至關重要。

雲端藥物發現平台市場的主要公司範例

  • Amazon Web Services
  • Clarivate
  • Dassault Systemes
  • Google Cloud
  • Accenture
  • Alibaba Cloud
  • Cognizant
  • HCLTech

專家訪談和行業洞察

本研究提出的觀點和見解是透過與整個價值鏈上的多位相關人員進行討論而形成的。本報告包含與以下行業相關人員的詳細訪談記錄：

  • 美國小型企業成長副總裁
  • 瑞士中型公司北美和南美區域經理

此外，本市場報告還包含與以下第三方進行的討論記錄：

  • 美國一家中型公司的執行長、首席架構師兼創辦人。
  • 美國一家大型公司的創辦人兼執行長
  • 一家美國中型公司的執行長
  • 加拿大小規模企業的執行長
  • 英國一家中型公司的前技術長
  • 美國一家中型公司前首席科學官
  • 一家印度中型公司的執行董事
  • 美國小型企業資料科學主管
  • 德國中型公司市場拓展（GTM）、策略夥伴關係與聯盟負責人
  • 美國一家大型公司，技術主管

基於雲端的藥物發現平台市場—研究範圍

  • 市場規模和機會分析：本報告對基於雲端的藥物發現平台市場進行了詳細分析，重點關注關鍵市場細分，例如 [A] 雲端服務類型、[B] 雲端類型、[C] 最終用戶、[D] 地區和 [E] 到 2035 年的銷售預測。
  • 市場概覽：這是對基於雲端的藥物發現平台提供者的整體詳細評估，包括對成立年份、公司規模、總部所在地、公司結構、雲端服務經營模式、品質認證、雲端類型、雲端服務類型、應用領域以及提供的其他功能和服務的分析。
  • 企業競爭分析：這是一項基準研究，它根據一組既定的假設和同行群體的參數，對總部位於北美、歐洲和亞太地區的雲端藥物發現平台提供者進行評估。
  • 公司簡介：詳細介紹提供雲端藥物發現平台的領先公司。內容包括公司概況、財務資訊、服務組合、近期發展和未來展望。
  • 夥伴關係與合作：我們根據合作年份、合作類型、重點領域、最活躍的參與者和地區（國內、國際、洲內、洲際協議）等參數，分析該領域相關人員關係與合作。
  • 成本降低分析：這項富有洞察力的分析估算了到 2035 年在北美、歐洲、亞太地區、中東和北非以及拉丁美洲部署基於雲端的藥物發現平台所帶來的預期成本節約。
  • 與預期技術升級相關的機會：本節概述了人工智慧、深度學習、機器學習和量子運算等關鍵基礎工具和技術，並分析了每項技術的創新程度和相關風險。
  • 市場影響分析：本報告分析了影響市場成長的各種因素，包括促進因素、限制因素、機會和挑戰。

目錄

第1章：序言

第2章：調查方法

第3章 市場動態

第4章 宏觀經濟指標

第5章摘要整理

第6章：引言

第7章 市場狀況

第8章：企業競爭力分析

第9章 公司簡介：基於雲端的藥物發現平台供應商

  • 章節概要
  • Microsoft
  • Google
  • Amazon Web Services
  • IBM
  • Accenture
  • Dassault Systemes
  • Alibaba Cloud
  • Huawei
  • Tencent Cloud

第10章夥伴關係與合作

第11章：成本降低分析

第12章：與預期技術升級相關的機遇

第13章 市場影響分析

第14章：全球雲端藥物發現平台市場

第15章：基於雲端的藥物發現平台市場（按雲端服務類型分類）

第16章：基於雲端的藥物發現平台市場（按雲類型分類）

第17章：基於雲端的藥物發現平台市場（以最終用戶分類）

第18章：基於雲端的藥物發現平台市場（按地區分類）

第19章：基於雲端的藥物發現平台市場－北美

第20章：基於雲端的藥物發現平台市場－歐洲

第21章 基於雲端的藥物發現平台市場－亞太地區

第22章 基於雲端的藥物發現平台市場－中東和北非

第23章：基於雲端的藥物發現平台市場－拉丁美洲

第24章 結論

第25章：高階主管洞察

第26章附錄一：表格形式數據

第27章 附錄二：公司與組織列表

簡介目錄
Product Code: RA100802

CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET: OVERVIEW

As per Roots Analysis, the global cloud based drug discovery platforms market is estimated to grow from USD 4.2 billion in the current year to USD 11.4 billion by 2035, reflecting a compound annual growth rate (CAGR) of approximately 11.7% during the forecast period.

Cloud Based Drug Discovery Platforms Market - IMG1

Cloud Based Drug Discovery Platforms Market: Growth and Trends

Cloud based drug discovery platforms are internet-hosted software ecosystems that provide scalable computing power, centralized data storage, and advanced analytics capabilities to accelerate the identification and optimization of new therapeutic compounds. These platforms support critical drug discovery workflows, including target identification, molecular modeling, virtual screening, lead optimization, multi-omics data management, and collaborative research across geographically distributed teams.

The growing complexity of modern drug discovery programs, which increasingly rely on large volumes of biological, chemical, genomic, transcriptomic, and clinical data, has intensified demand for platforms capable of processing and interpreting such datasets at scale. Traditional on-premises infrastructure often constrains scalability, computational flexibility, and cross-functional collaboration, limitations that cloud based platforms are well positioned to address through centralized data access, elastic high-performance computing capacity, and native integration with artificial intelligence and machine learning tools.

Adoption is further supported by the broader industry shift toward data driven, AI enabled discovery models. Pharmaceutical and biotechnology companies are increasingly deploying cloud infrastructure to improve hit identification, predict candidate properties, reduce experimental burden, and accelerate early-stage decision-making. Distributed research teams across discovery, informatics, manufacturing, and external partners increasingly rely on cloud environments to improve collaboration as drug discovery programs involve more contract research organizations and technology providers.

Notably, the continued advancement in AI enabled discovery tools, expanding cloud computing infrastructure, and the proliferation of large-scale technology partnerships between pharmaceutical companies and cloud providers are expected to sustain long-term market growth.

Growth Drivers: Factors Fueling Market Expansion

Growth in the cloud based drug discovery platforms market is being driven by the rising adoption of AI enabled discovery workflows. Pharmaceutical and biotechnology companies are increasingly using artificial intelligence within cloud based platforms to accelerate target identification, molecule generation, virtual screening, lead optimization, and candidate prioritization. Cloud infrastructure enables these workflows by offering scalable computing power, centralized data access, and the capacity to run multiple predictive models in parallel, without the capital burden of building complex internal computing infrastructure. This trend is reflected in recent platform launches Amazon Web Services introduced Amazon Bio Discovery, granting access to more than forty AI biology models alongside AI-guided model selection, computational workflow design, and wet lab validation support.

Additionally, the growing need for scalable data integration and collaborative research. Modern drug discovery depends on the integration of large biological, chemical, genomic, transcriptomic, and real-world datasets. Cloud based platforms allow research teams to store, analyze, and share such datasets across distributed discovery networks, strengthening collaboration between pharmaceutical companies, technology providers, academic institutes, and contract research organizations. Large-scale cloud solution providers are leveraging partnerships to expand their globally reach. Merck and Google Cloud announced a multiyear collaboration valued at up to USD 1 billion to deploy AI and cloud infrastructure across research, development, manufacturing, commercial, and corporate functions.

Market Challenges: Critical Barriers Hindering Progress

Despite strong momentum, the cloud based drug discovery platforms market faces several constraints. Foremost among these are concerns related to data security, intellectual property protection, and regulatory compliance. These platforms handle highly sensitive data, including proprietary molecular structures, target biology, screening results, patient-linked datasets, and competitive pipeline information, making data security, access control, auditability, and vendor governance critical considerations for adoption. Pharmaceutical companies must also ensure that cloud based systems align with regulatory and data protection requirements, particularly where platforms support regulated research workflows or generate evidence used in development decisions.

Additionally, the effectiveness of cloud based drug discovery platforms depends heavily on the quality and compatibility of input datasets, yet many organizations continue to manage fragmented research data across legacy systems, internal databases, laboratory platforms, and external sources, complicating integration. In addition, AI models used within these platforms require rigorous validation, explainability, and context-specific performance assessment before stakeholders can rely on their outputs for discovery and development decision-making. System interoperability and integration with legacy research infrastructure remain further considerations for prospective adopters.

Cloud Based Drug Discovery Platforms Market: Key Insights

The report delves into the current state of the cloud based drug discovery platforms market and identifies potential growth opportunities within the industry, particularly from a distributor and channel-partner perspective. Some key findings include:

  • Increasing Capital Investment: More than USD 4 billion has been invested in cloud-native drug discovery technology providers, AI-enabled research platforms, and computational biology companies in recent years through venture capital, private equity, and strategic funding rounds. British biotech Relation Therapeutics signed a collaboration with GSK worth up to USD 110 million to develop AI-driven drug discovery models and human cellular datasets.
  • Accelerating Strategic Collaborations: The market is witnessing a rise in strategic partnerships between cloud service providers, pharmaceutical companies, biotechnology firms, and AI platform developers. These collaborations focus on integrating high-performance computing, machine learning, and multi-omics data management to accelerate drug discovery workflows, reduce computational bottlenecks, and support decentralized global research teams. Bristol Myers Squibb announced deployment of NVIDIA's next-generation DGX SuperPOD AI infrastructure to accelerate drug discovery, stating AI has already reduced development timelines by 20-30%.
  • Supportive Regulatory and Digital Infrastructure: Regulatory agencies are increasingly recognizing the role of AI, cloud computing, and digital technologies in pharmaceutical R&D through updated guidance on electronic records, AI model validation, data integrity, and Good Machine Learning Practices (GMLP). At the same time, advancements in cybersecurity standards and cloud compliance frameworks have strengthened industry confidence in adopting cloud-hosted drug discovery platforms.
  • Future Focus Areas: Future market growth will depend on improving interoperability across laboratory information management systems (LIMS), electronic lab notebooks (ELNs), genomic databases, and AI discovery platforms. Wider adoption of federated learning, secure multi-party data sharing, explainable AI, and standardized cloud data architectures is expected to enhance cross-organizational collaboration while addressing data privacy, regulatory compliance, and intellectual property protection challenges. These developments are likely to shape long-term platform adoption and remain key indicators for technology providers and investors.

Cloud Based Drug Discovery Platforms Market Segments

Roots Analysis segments the global Cloud Based Drug Discovery Platforms opportunity across the following parameters:

By Type of Cloud Service

  • Software as a Service
  • Infrastructure as a Service
  • Platform as a Service
  • Others

By Type of Cloud

  • Hybrid Cloud
  • Public Cloud
  • Private Cloud

By End User

  • Pharmaceutical and Life Science Companies
  • CROs
  • Others

By Geographical Regions

  • North America
  • Europe
  • Asia-Pacific
  • Middle East and North Africa
  • Latin America

Cloud Based Drug Discovery Platforms Market: Key Segment Insights

Software as a Service Leads the Cloud Based Drug Discovery Platforms Market

Based on our market assessment, the software as a service (SaaS) segment currently represents the largest share of the cloud based drug discovery platforms market. This leadership is attributed to lower upfront infrastructure requirements, faster deployment timelines, and subscription-based access to advanced discovery tools. These factors make SaaS an attractive entry point for organizations of varying size and computational maturity.

Looking ahead, the platform as a service (PaaS) segment is likely to register the highest CAGR during the forecast period. This growth can be attributed to the fact that PaaS enables pharmaceutical and biotechnology companies to build, integrate, and scale customized discovery workflows spanning AI modeling, molecular simulation, data analytics, and collaborative research environments.

Hybrid Cloud Retains the Largest Share by Type of Cloud

According to our analysis, the hybrid cloud segment accounts for the largest share of the cloud-based drug discovery market, as it enables pharmaceutical and biotechnology companies to balance computational scalability with stringent security and regulatory requirements. Drug discovery workflows generate vast volumes of sensitive data, including genomic datasets, molecular structures, clinical evidence, and proprietary AI models, making complete migration to public cloud environments impractical for many organizations. Hybrid cloud architecture enables companies to keep sensitive intellectual property and regulated data within private infrastructure while using public clouds for compute-intensive tasks such as AI model training, virtual screening, and large-scale omics analysis.

In addition, hybrid cloud deployments facilitate seamless collaboration across geographically distributed research teams, contract research organizations (CROs), academic institutions, and technology partners without compromising governance over critical data assets. As pharmaceutical companies continue to adopt AI-driven drug discovery and multi-partner R&D models while maintaining compliance with evolving data privacy and regulatory standards, hybrid cloud environments are expected to remain the preferred deployment model, reinforcing their leading position in the market.

North America Maintains Market Leadership

North America is expected to retain its position as the largest regional market for cloud based drug discovery platforms through 2035. The region's leadership is driven by the strong presence of pharmaceutical and biotechnology companies, advanced cloud infrastructure, widespread adoption of AI-enabled drug discovery platforms, and high research and development investment.

Asia-Pacific Emerges as the Fastest-Growing Regional Market

The Asia-Pacific cloud based drug discovery platforms market is anticipated to witness the highest CAGR during the forecast period. Growth in the region is being driven by expanding pharmaceutical research activity, rising biotechnology investment, and growing demand for cost-efficient discovery solutions. Countries such as China, India, Japan, and South Korea are strengthening their digital health and life sciences ecosystems, accelerating the adoption of cloud-based platforms for collaborative drug discovery, data management, and computational research.

Pharmaceutical and Life Science Companies Account for the Largest End-User Share

According to our analysis, pharmaceutical and life science companies account for the largest share of the cloud-based drug discovery market. This dominance is due to their extensive involvement across the drug discovery value chain and sustained investments in digital research capabilities. These organizations generate and manage vast volumes of biological, chemical, genomic, and clinical data that require scalable computing infrastructure for storage, integration, and analysis. Cloud-based platforms enable them to accelerate target identification, virtual screening, molecular modeling, AI-driven predictive analytics, and lead optimization while reducing dependence on costly on-premises infrastructure.

In addition, pharmaceutical and life science companies increasingly rely on cloud environments to support collaboration across geographically distributed research teams, contract research organizations (CROs), academic institutions, and technology partners. The ability to securely share data, integrate laboratory and computational workflows, and rapidly scale computing resources has become essential as drug discovery programs grow more data-intensive and AI-driven.

Example Players in Cloud Based Drug Discovery Platforms Market

  • Amazon Web Services
  • Clarivate
  • Dassault Systemes
  • Google Cloud
  • Accenture
  • Alibaba Cloud
  • Cognizant
  • HCLTech

Expert Interview and Industry Insights

The opinions and insights presented in this study were shaped by discussions with multiple stakeholders across the value chain. The research report features detailed transcripts of interviews held with the following industry participants:

  • Vice President Growth, Small Company, US
  • Regional Manager North and South America, Small Company, Switzerland

In addition, the market report includes transcripts of the following other third-party discussions:

  • Chief Executive Officer, Chief Architect and Founder, Mid-sized Company, US
  • Founder and Chief Executive Officer, Large Company, US
  • Chief Executive Officer, Mid-sized Company, US
  • Chief Executive Officer, Small Company, Canada
  • Former Chief Technology Officer, Mid-sized Company, UK
  • Former Chief Scientific Officer, Mid-sized Company, US
  • Managing Director, Mid-sized Company, India
  • Head of Data Science, Small Company, US
  • Head of GTM, Strategic Partnerships & Alliances, Mid-sized Company, Germany
  • Technical Lead, Large Company, US

CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET: RESEARCH COVERAGE

  • Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the cloud based drug discovery platforms market, focusing on key market segments, including [A] type of cloud service, [B] type of cloud, [C] end user, [D] geographical regions and [E] sales forecast, till 2035.
  • Market Landscape: A detailed assessment of the overall cloud based drug discovery platform providers landscape, featuring analysis by year of establishment, company size, location of headquarters, type of company, cloud service business model, quality certifications, type of cloud, type of cloud services, area of application, and additional capabilities and services offered.
  • Company Competitiveness Analysis: A benchmarking exercise evaluating cloud based drug discovery platform providers headquartered in North America, Europe, and Asia-Pacific, based on a defined set of assumptions and peer group parameters.
  • Company Profiles: In-depth profiles of prominent players engaged in offering cloud based drug discovery platforms, featuring information on company overview, financial information, service portfolio, and recent developments and future outlook.
  • Partnerships and Collaborations: An analysis of partnerships and collaborations inked by stakeholders in this domain, based on parameters such as year of partnership, type of partnership, focus area, most active players, and geography (local, international, intracontinental and intercontinental agreements).
  • Cost Saving Analysis: An insightful analysis estimating the likely cost savings associated with the adoption of cloud based drug discovery platforms across North America, Europe, Asia-Pacific, Middle East and North Africa, and Latin America, till 2035.
  • Anticipated Technology Upgrades and Affiliated Opportunities: A review of key enabling tools and technologies, including artificial intelligence, deep learning, machine learning, and quantum computing, along with an extent of innovation versus associated risk analysis for each.
  • Market Impact Analysis: The report analyzes various factors, such as drivers, restraints, opportunities, and challenges affecting market growth.

Key Questions Answered in this Report

  • Which are the leading companies in the cloud based drug discovery platforms market?
  • Which region dominates the cloud based drug discovery platforms market?
  • What are the key trends observed in the cloud based drug discovery platforms market?
  • What factors are likely to influence the evolution of this market?
  • What are the primary challenges faced by cloud based drug discovery platform developers?
  • What is the current and future market size?
  • What is the CAGR of this market?
  • How is the current and future market opportunity likely to be distributed across key market segments?

Reasons to Buy this Report

This report has been specifically developed to support distributors, channel partners, and business development teams evaluating entry into the cloud based drug discovery platforms market.

  • The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
  • The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
  • The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
  • The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
  • The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
  • The report allows for more effective communication with the audience and in building strong business relations.

Additional Benefits

  • Complementary Insights Pack
  • Complementary PPT Insights Pack
  • Complementary Excel Data Packs for all Analytical Modules in the Report
  • 15% Free Content Customization
  • Detailed Report Walkthrough Session with Research Team
  • Free Updated report if the report is 6-12 months old or older

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Introduction
  • 1.2. Market Share Insights
  • 1.3. Key Market Insights
  • 1.4. Report Coverage
  • 1.5. Key Questions Answered
  • 1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

  • 2.1. Chapter Overview
  • 2.2. Research Assumptions
    • 2.2.1. Market Landscape and Market Trends
    • 2.2.2. Market Forecast and Opportunity Analysis
    • 2.2.3. Comparative Analysis
  • 2.3. Database Building
    • 2.3.1. Data Collection
    • 2.3.2. Data Validation
    • 2.3.3. Data Analysis
  • 2.4. Project Methodology
    • 2.4.1. Secondary Research
      • 2.4.1.1. Annual Reports
      • 2.4.1.2. Academic Research Papers
      • 2.4.1.3. Company Websites
      • 2.4.1.4. Investor Presentations
      • 2.4.1.5. Regulatory Filings
      • 2.4.1.6. White Papers
      • 2.4.1.7. Industry Publications
      • 2.4.1.8. Conferences and Seminars
      • 2.4.1.9. Government Portals
      • 2.4.1.10. Media and Press Releases
      • 2.4.1.11. Newsletters
      • 2.4.1.12. Industry Databases
      • 2.4.1.13. Roots Proprietary Databases
      • 2.4.1.14. Paid Databases and Sources
      • 2.4.1.15. Social Media Portals
      • 2.4.1.16. Other Secondary Sources
    • 2.4.2. Primary Research
      • 2.4.2.1. Types of Primary Research
        • 2.4.2.1.1. Qualitative Research
        • 2.4.2.1.2. Quantitative Research
        • 2.4.2.1.3. Hybrid Approach
      • 2.4.2.2. Advantages of Primary Research
      • 2.4.2.3. Techniques for Primary Research
        • 2.4.2.3.1. Interviews
        • 2.4.2.3.2. Surveys
        • 2.4.2.3.3. Focus Groups
        • 2.4.2.3.4. Observational Research
        • 2.4.2.3.5. Social Media Interactions
      • 2.4.2.4. Key Opinion Leaders Considered in Primary Research
        • 2.4.2.4.1. Company Executives (CXOs)
        • 2.4.2.4.2. Board of Directors
        • 2.4.2.4.3. Company Presidents and Vice Presidents
        • 2.4.2.4.4. Research and Development Heads
        • 2.4.2.4.5. Technical Experts
        • 2.4.2.4.6. Subject Matter Experts
        • 2.4.2.4.7. Scientists
        • 2.4.2.4.8. Doctors and Other Healthcare Providers
      • 2.4.2.5. Ethics and Integrity
        • 2.4.2.5.1. Research Ethics
        • 2.4.2.5.2. Data Integrity
    • 2.4.3. Analytical Tools and Databases
  • 2.5. Robust Quality Control

3. MARKET DYNAMICS

  • 3.1. Chapter Overview
  • 3.2. Forecast Methodology
    • 3.2.1. Top-down Approach
    • 3.2.2. Bottom-up Approach
    • 3.2.3. Hybrid Approach
  • 3.3. Market Assessment Framework
    • 3.3.1. Total Addressable Market (TAM)
    • 3.3.2. Serviceable Addressable Market (SAM)
    • 3.3.3. Serviceable Obtainable Market (SOM)
    • 3.3.4. Currently Acquired Market (CAM)
  • 3.4. Forecasting Tools and Techniques
    • 3.4.1. Qualitative Forecasting
    • 3.4.2. Correlation
    • 3.4.3. Regression
    • 3.4.4. Extrapolation
    • 3.4.5. Convergence
    • 3.4.6. Sensitivity Analysis
    • 3.4.7. Scenario Planning
    • 3.4.8. Data Visualization
    • 3.4.9. Time Series Analysis
    • 3.4.10. Forecast Error Analysis
  • 3.5. Key Considerations
    • 3.5.1. Demographics
    • 3.5.2. Government Regulations
    • 3.5.3. Reimbursement Scenarios
    • 3.5.4. Market Access
    • 3.5.5. Supply Chain
    • 3.5.6. Industry Consolidation
    • 3.5.7. Pandemic / Unforeseen Disruptions Impact
  • 3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

  • 4.1. Chapter Overview
  • 4.2. Market Dynamics
    • 4.2.1. Time Period
      • 4.2.1.1. Historical Trends
      • 4.2.1.2. Current and Forecasted Estimates
    • 4.2.2. Currency Coverage
      • 4.2.2.1. Major Currencies Affecting the Market
      • 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
      • 4.2.2.3. Impact of Currency Fluctuations on the Industry
    • 4.2.3. Foreign Currency Exchange Rate
      • 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
      • 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
    • 4.2.4. Recession
      • 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
      • 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
    • 4.2.5. Inflation
      • 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
      • 4.2.5.2. Potential Impact of Inflation on the Market Evolution
    • 4.2.6. Interest Rates
      • 4.2.6.1. Interest Rates and Their Impact on the Market
      • 4.2.6.2. Strategies for Managing Interest Rate Risk
    • 4.2.7. Commodity Flow Analysis
      • 4.2.7.1. Type of Commodity
      • 4.2.7.2. Origins and Destinations
      • 4.2.7.3. Values and Weights
      • 4.2.7.4. Modes of Transportation
    • 4.2.8. Global Trade Dynamics
      • 4.2.8.1. Import Scenario
      • 4.2.8.2. Export Scenario
      • 4.2.8.3. Trade Policies
      • 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
      • 4.2.8.5. Impact of Trade Barriers on the Market
    • 4.2.9. War Impact Analysis
      • 4.2.9.1. Russian-Ukraine War
      • 4.2.9.2. Israel-Hamas War
    • 4.2.10. COVID Impact / Related Factors
      • 4.2.10.1. Global Economic Impact
      • 4.2.10.2. Industry-specific Impact
      • 4.2.10.3. Government Response and Stimulus Measures
      • 4.2.10.4. Future Outlook and Adaptation Strategies
    • 4.2.11. Other Indicators
      • 4.2.11.1. Fiscal Policy
      • 4.2.11.2. Consumer Spending
      • 4.2.11.3. Gross Domestic Product
      • 4.2.11.4. Employment
      • 4.2.11.5. Taxes
      • 4.2.11.6. Stock Market Performance
      • 4.2.11.7. Cross Border Dynamics
  • 4.3. Conclusion

5. EXECUTIVE SUMMARY

6. INTRODUCTION

  • 6.1. Chapter Overview
  • 6.2. Overview of Cloud Computing
    • 6.2.1. Types of Clouds and Cloud Services
    • 6.2.2. Cloud Computing in Drug Discovery
    • 6.2.3. Benefits and Limitations of Cloud Computing
  • 6.3. Concluding Remarks

7. MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Cloud Based Drug Discovery Platform Providers: Overall Market Landscape
    • 7.2.1. Analysis by Year of Establishment
    • 7.2.2. Analysis by Company Size
    • 7.2.3. Analysis by Location of Headquarters (Region)
    • 7.2.4. Analysis by Location of Headquarters (Country)
    • 7.2.5. Analysis by Type of Company
    • 7.2.6. Analysis by Cloud Service Business Model
    • 7.2.7. Analysis by Quality Certifications
    • 7.2.8. Analysis by Type of Cloud
    • 7.2.9. Analysis by Type of Cloud Services
    • 7.2.10. Analysis by Area of Application
    • 7.2.11. Analysis by Additional Capabilities
    • 7.2.12. Analysis by Additional Services Offered

8. COMPANY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Assumptions and Key Parameters
  • 8.3. Methodology
  • 8.4. Overview of Peer Groups
  • 8.5. Company Competitiveness Analysis
    • 8.5.1. Cloud Based Drug Discovery Platform Providers Headquartered in North America
    • 8.5.2. Cloud Based Drug Discovery Platform Providers Headquartered in Europe
    • 8.5.3. Cloud Based Drug Discovery Platform Providers Headquartered in Asia-Pacific

9. COMPANY PROFILES: CLOUD BASED DRUG DISCOVERY PLATFORM PROVIDERS

  • 9.1. Chapter Overview
  • 9.2. Microsoft
    • 9.2.1. Company Overview
    • 9.2.2. Financial Information
    • 9.2.3. Service Portfolio
    • 9.2.4. Recent Developments and Future Outlook
  • 9.3. Google
  • 9.4. Amazon Web Services
  • 9.5. IBM
  • 9.6. Accenture
  • 9.7. Dassault Systemes
  • 9.8. Alibaba Cloud
  • 9.9. Huawei
  • 9.10. Tencent Cloud

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Cloud Based Drug Discovery Platform Providers: Partnerships and Collaborations
    • 10.3.1. Analysis by Year of Partnership
    • 10.3.2. Analysis by Type of Partnership
    • 10.3.3. Analysis by Year and Type of Partnership
    • 10.3.4. Analysis by Focus Area
    • 10.3.5. Most Active Players: Analysis by Number of Partnerships
    • 10.3.6. Analysis by Geography
      • 10.3.6.1. Local and International Agreements
      • 10.3.6.2. Intracontinental and Intercontinental Agreements

11. COST SAVING ANALYSIS

  • 11.1. Chapter Overview
  • 11.2. Key Assumptions and Methodology
  • 11.3. Likely Cost Savings Associated with Cloud Based Drug Discovery Platforms, till 2035
    • 11.3.1. Likely Cost Savings Associated with Cloud Based Drug Discovery Platforms in North America, till 2035
    • 11.3.2. Likely Cost Savings Associated with Cloud Based Drug Discovery Platforms in Europe, till 2035
    • 11.3.3. Likely Cost Savings Associated with Cloud Based Drug Discovery Platforms in Asia-Pacific, till 2035
    • 11.3.4. Likely Cost Savings Associated with Cloud Based Drug Discovery Platforms in Middle East and North Africa, till 2035
    • 11.3.5. Likely Cost Savings Associated with Cloud Based Drug Discovery Platforms in Latin America, till 2035
  • 11.4. Concluding Remarks: Cost Saving Scenarios

12. ANTICIPATED TECHNOLOGY UPGRADES AND AFFILIATED OPPORTUNITIES

  • 12.1. Chapter Overview
  • 12.2. Key Assumptions and Methodology
  • 12.3. Key Tools and Technologies
    • 12.3.1. Artificial Intelligence
      • 12.3.1.1. Artificial Intelligence in Drug Discovery
      • 12.3.1.2. Likely Cost-Savings by Integrating Artificial Intelligence with Cloud Computing
    • 12.3.2. Deep Learning
      • 12.3.2.1. Deep Learning in Drug Discovery
      • 12.3.2.2. Likely Cost-Savings by Integrating Deep Learning with Cloud Computing
    • 12.3.3. Machine Learning
      • 12.3.3.1. Machine Learning in Drug Discovery
      • 12.3.3.2. Likely Cost-Savings by Integrating Machine Learning with Cloud Computing
    • 12.3.4. Quantum Computing
      • 12.3.4.1. Quantum Computing in Drug Discovery
      • 12.3.4.2. Likely Cost-Savings by Integrating Quantum Computing with Cloud Computing
  • 12.4. Extent of Innovation versus Associated Risk Analysis
    • 12.4.1. Results and Discussion

13. MARKET IMPACT ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Market Drivers
  • 13.3. Market Restraints
  • 13.4. Market Opportunities
  • 13.5. Market Challenges
  • 13.6. Conclusion

14. GLOBAL CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET

  • 14.1. Chapter Overview
  • 14.2. Key Assumptions and Methodology
  • 14.3. Global Cloud Based Drug Discovery Platforms Market, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 14.3.1. Roots Analysis Perspective on Market Growth
    • 14.3.2. Scenario Analysis
      • 14.3.2.1. Conservative Scenario
      • 14.3.2.2. Optimistic Scenario
  • 14.4. Key Market Segmentations

15. CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET, BY TYPE OF CLOUD SERVICE

  • 15.1. Chapter Overview
  • 15.2. Key Assumptions and Methodology
  • 15.3. Cloud Based Drug Discovery Platforms Market: Distribution by Type of Cloud Service
    • 15.3.1. Cloud Based Drug Discovery Platforms Market for Software as a Service (SaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 15.3.2. Cloud Based Drug Discovery Platforms Market for Infrastructure as a Service (IaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 15.3.3. Cloud Based Drug Discovery Platforms Market for Platform as a Service (PaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 15.3.4. Cloud Based Drug Discovery Platforms Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 15.4. Data Triangulation and Validation

16. CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET, BY TYPE OF CLOUD

  • 16.1. Chapter Overview
  • 16.2. Key Assumptions and Methodology
  • 16.3. Cloud Based Drug Discovery Platforms Market: Distribution by Type of Cloud
    • 16.3.1. Cloud Based Drug Discovery Platforms Market for Hybrid Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 16.3.2. Cloud Based Drug Discovery Platforms Market for Public Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 16.3.3. Cloud Based Drug Discovery Platforms Market for Private Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 16.4. Data Triangulation and Validation

17. CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET, BY END USER

  • 17.1. Chapter Overview
  • 17.2. Key Assumptions and Methodology
  • 17.3. Cloud Based Drug Discovery Platforms Market: Distribution by End User
    • 17.3.1. Cloud Based Drug Discovery Platforms Market for Pharmaceutical and Life Science Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 17.3.2. Cloud Based Drug Discovery Platforms Market for CROs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 17.3.3. Cloud Based Drug Discovery Platforms Market for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 17.4. Data Triangulation and Validation

18. CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET, BY GEOGRAPHICAL REGIONS

  • 18.1. Chapter Overview
  • 18.2. Key Assumptions and Methodology
  • 18.3. Cloud Based Drug Discovery Platforms Market: Distribution by Geographical Regions
    • 18.3.1. Cloud Based Drug Discovery Platforms Market in North America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 18.3.2. Cloud Based Drug Discovery Platforms Market in Europe, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 18.3.3. Cloud Based Drug Discovery Platforms Market in Asia-Pacific, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 18.3.4. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 18.3.5. Cloud Based Drug Discovery Platforms Market in Latin America, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 18.4. Cloud Based Drug Discovery Platforms Market, by Geographical Regions: Market Dynamics Assessment
    • 18.4.1. Penetration Growth (P-G) Matrix
    • 18.4.2. Market Movement Analysis
  • 18.5. Data Triangulation and Validation

19. CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET: NORTH AMERICA

  • 19.1. Cloud Based Drug Discovery Platforms Market in North America: Distribution by Type of Cloud Service
    • 19.1.1. Cloud Based Drug Discovery Platforms Market in North America for Software as a Service (SaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.1.2. Cloud Based Drug Discovery Platforms Market in North America for Infrastructure as a Service (IaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.1.3. Cloud Based Drug Discovery Platforms Market in North America for Platform as a Service (PaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.1.4. Cloud Based Drug Discovery Platforms Market in North America for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 19.2. Cloud Based Drug Discovery Platforms Market in North America: Distribution by Type of Cloud
    • 19.2.1. Cloud Based Drug Discovery Platforms Market in North America for Hybrid Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.2.2. Cloud Based Drug Discovery Platforms Market in North America for Public Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.2.3. Cloud Based Drug Discovery Platforms Market in North America for Private Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 19.3. Cloud Based Drug Discovery Platforms Market in North America: Distribution by End User
    • 19.3.1. Cloud Based Drug Discovery Platforms Market in North America for Pharmaceutical and Life Science Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.3.2. Cloud Based Drug Discovery Platforms Market in North America for CROs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 19.3.3. Cloud Based Drug Discovery Platforms Market in North America for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

20. CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET: EUROPE

  • 20.1. Cloud Based Drug Discovery Platforms Market in Europe: Distribution by Type of Cloud Service
    • 20.1.1. Cloud Based Drug Discovery Platforms Market in Europe for Software as a Service (SaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 20.1.2. Cloud Based Drug Discovery Platforms Market in Europe for Infrastructure as a Service (IaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 20.1.3. Cloud Based Drug Discovery Platforms Market in Europe for Platform as a Service (PaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 20.1.4. Cloud Based Drug Discovery Platforms Market in Europe for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 20.2. Cloud Based Drug Discovery Platforms Market in Europe: Distribution by Type of Cloud
    • 20.2.1. Cloud Based Drug Discovery Platforms Market in Europe for Hybrid Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 20.2.2. Cloud Based Drug Discovery Platforms Market in Europe for Public Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 20.2.3. Cloud Based Drug Discovery Platforms Market in Europe for Private Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 20.3. Cloud Based Drug Discovery Platforms Market in Europe: Distribution by End User
    • 20.3.1. Cloud Based Drug Discovery Platforms Market in Europe for Pharmaceutical and Life Science Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 20.3.2. Cloud Based Drug Discovery Platforms Market in Europe for CROs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 20.3.3. Cloud Based Drug Discovery Platforms Market in Europe for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

21. CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET: ASIA-PACIFIC

  • 21.1. Cloud Based Drug Discovery Platforms Market in Asia-Pacific: Distribution by Type of Cloud Service
    • 21.1.1. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for Software as a Service (SaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.1.2. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for Infrastructure as a Service (IaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.1.3. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for Platform as a Service (PaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.1.4. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 21.2. Cloud Based Drug Discovery Platforms Market in Asia-Pacific: Distribution by Type of Cloud
    • 21.2.1. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for Hybrid Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.2.2. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for Public Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.2.3. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for Private Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 21.3. Cloud Based Drug Discovery Platforms Market in Asia-Pacific: Distribution by End User
    • 21.3.1. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for Pharmaceutical and Life Science Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.3.2. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for CROs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 21.3.3. Cloud Based Drug Discovery Platforms Market in Asia-Pacific for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

22. CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET: MIDDLE EAST AND NORTH AFRICA

  • 22.1. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa: Distribution by Type of Cloud Service
    • 22.1.1. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for Software as a Service (SaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 22.1.2. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for Infrastructure as a Service (IaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 22.1.3. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for Platform as a Service (PaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 22.1.4. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 22.2. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa: Distribution by Type of Cloud
    • 22.2.1. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for Hybrid Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 22.2.2. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for Public Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 22.2.3. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for Private Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 22.3. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa: Distribution by End User
    • 22.3.1. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for Pharmaceutical and Life Science Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 22.3.2. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for CROs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 22.3.3. Cloud Based Drug Discovery Platforms Market in Middle East and North Africa for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)

23. CLOUD BASED DRUG DISCOVERY PLATFORMS MARKET: LATIN AMERICA

  • 23.1. Cloud Based Drug Discovery Platforms Market in Latin America: Distribution by Type of Cloud Service
    • 23.1.1. Cloud Based Drug Discovery Platforms Market in Latin America for Software as a Service (SaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 23.1.2. Cloud Based Drug Discovery Platforms Market in Latin America for Infrastructure as a Service (IaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 23.1.3. Cloud Based Drug Discovery Platforms Market in Latin America for Platform as a Service (PaaS), Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 23.1.4. Cloud Based Drug Discovery Platforms Market in Latin America for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 23.2. Cloud Based Drug Discovery Platforms Market in Latin America: Distribution by Type of Cloud
    • 23.2.1. Cloud Based Drug Discovery Platforms Market in Latin America for Hybrid Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 23.2.2. Cloud Based Drug Discovery Platforms Market in Latin America for Public Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 23.2.3. Cloud Based Drug Discovery Platforms Market in Latin America for Private Cloud, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • 23.3. Cloud Based Drug Discovery Platforms Market in Latin America: Distribution by End User
    • 23.3.1. Cloud Based Drug Discovery Platforms Market in Latin America for Pharmaceutical and Life Science Companies, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 23.3.2. Cloud Based Drug Discovery Platforms Market in Latin America for CROs, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
    • 23.3.3. Cloud Based Drug Discovery Platforms Market in Latin America for Others, Historical Trends (since 2021) and Forecasted Estimates (till 2035)
  • *Detailed information is available in the Excel Data Packs shared along with the report.**

24. CONCLUDING REMARKS

25. EXECUTIVE INSIGHTS

26. APPENDIX I: TABULATED DATA

27. APPENDIX II: LIST OF COMPANIES AND ORGANIZATIONS